As reported in Table 1, most of patients with T2DM were treated with metformin (78.6%) followed by sulphonylureas (28.6%), DPP-4 inhibitors (23.7%), GLP-1 receptor agonists (18.3%), SGLT-2 inhibitors (9.8%) or pioglitazone (8.5%). The gene discussed is GLP1R; the disease is type 2 diabetes mellitus.